1710768-30-1

Basic information

• Product Name: (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one
• CAS NO: 1710768-30-1
• Molecular Weight: 581.721
• Mol File: 1710768-30-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one(1710768-30-1)
• EPA Substance Registry System: (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one(1710768-30-1)

Safety Data

• Hazardous Substances Data: 1710768-30-1(Hazardous Substances Data)

Usage

Description

(R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one is a complex organic compound with a unique structure that features a piperidin-1-yl group, a pyrazolo[3,4-d]-pyrimidin-1-yl group, and a piperazin-1-yl group, among others. The presence of a but-2-en-1-one group imparts a characteristic double bond to the molecule. The inclusion of an aminoethyl group and an amino group suggests potential biological activity, making it a candidate for pharmaceutical applications and drug development.

Uses

Used in Pharmaceutical Industry:
(R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one is used as a potential pharmaceutical agent for [application reason] due to its complex structure and the presence of biologically active groups.
Used in Research and Development:
In the field of chemical research and development, (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one is used as a compound for exploring new drug candidates and treatment options, leveraging its specific structural features and potential biological activity.

Upstream product

• 140447-78-5 tert‐butyl N‐[2‐(piperazin‐1‐yl)ethyl]carbamate 
• 140-31-8 aminoethylpiperazine 
• 1022150-12-4 (R)-3-(4-phenoxyphenyl)-1-(piperidine-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine 
• 1022150-11-3 (3R)‐4‐amino‐3‐(4-phenoxyphenyl)‐1‐(1‐tert-butoxycarbonylpiperidine-3-yl)-1H-pyrazolo[3,4-d]pyrimidine 
• 100450-84-8 N-[phenylmethylidene]-2-piperazin-1-ylethanamine 
• 330786-24-8 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 151266-23-8 4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 500013-42-3 benzyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)piperazine-1-carboxylate 
• 104740-55-8 4-(2-aminoethyl)-1-piperazinecarboxylic acid phenylmethyl ester 
• 2380-63-4 4-Aminopyrazolo<3,4-d>pyrimidin 
• 1022150-13-5 (2E)‐4‐[4‐(2‐{[(tert‐butoxy)carbonyl]amino}ethyl)piperazin‐1‐yl]but‐2‐enoic acid 

Relevant articles and documents

Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: A comparative study

Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) and has been approved for the treatment of haematological malignancies, such as chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenstr?m's macroglobulinemia. The covalent and irreversible nature of its molecular mode of action allows identification and monitoring of its target in an activity-based protein profiling (ABPP) setting. Fluorescent and biotinylated ibrutinib derivatives have appeared in the literature in recent years to monitor BTK in vitro and in situ. The work described here complements this existing methodology and pertains a comparative study on the efficacy of direct and two-step bioorthogonal ABPP of BTK.